Effects of a single dose of psilocybin on diet-induced weight loss in obese mice Authors: Ryan J. Keenan, Rifa T. Haque, Xiangjun Jin, Tomris Mustafa, Jihane Homman-Ludiye, Kayla Elysee, Zi Shan Wee, Stephanie E. Simonds, Claire J. Foldi, Michael A. Cowley Published: 2026 ABSTRACT Prolonged obesity induces enduring structural changes within neural circuits that contribute to maintaining the body at an elevated/obese body weight. These circuits regulate various mechanisms which can inhibit extreme or persistent weight loss. Therefore, a potential therapeutic strategy to facilitate weight loss is to promote structural plasticity within the brain. Psychedelic compounds, such as psilocybin, promote neural plasticity caused by a rapid and persistent growth of dendritic spines, which can facilitate the remodelling of neural circuits. Preclinical and clinical studies using psychedelic compounds have demonstrated efficacy for various neuropsychiatric disorders, which are often comorbid with obesity, and share underlying neural mechanisms. Here, we evaluate the effects of a single dose of psilocybin on body weight, food intake and energy expenditure in diet-induced obese (DIO) mice switched onto a low-fat chow. Psilocybin exacerbated diet-induced weight loss over a four-week period in DIO mice and increased the susceptibility for mice to exhibit more profound weight loss. Psilocybin appears to exert these effects predominantly through modulating food intake, with no influence on energy expenditure. No differences were observed in body weight or food intake in DIO mice maintained on a high-fat diet, indicating psilocybin does not necessarily directly promote weight loss or reduce food intake. Rather, it may help facilitate weight loss, provided it is administered in combination with other weight loss promoting interventions. Additional experimentation is required to examine the precise mechanisms involved; however, this data supports further investigation into the use of psychedelic compounds as an adjunct therapy for obesity. Introduction Obesity is a global epidemic and is a major contributor to the onset of metabolic diseases [1]. Hypothalamic nuclei play a key role in regulating feeding behaviour, hunger, satiation and energy homeostasis [2], which influences long-term energy balance and body weight. Body weight maintenance is also driven by complex interactions between these homeostatic circuits and cognitive or emotional stimuli/processes [3]. Additionally, obesity has been linked with altered prefrontal cortex (PFC) function [4–6] which leads to deficits in cognitive control over behaviour. Intensive dieting is often an ineffective strategy to combat obesity as these diets can be difficult to maintain, and any weight lost during the initial dieting period is commonly regained [7]. One plausible explanation for the often rapid regain of weight and failure of many diets is that following an extended period of obesity, the brain has established a long-term “set point” at the higher weight [8]. Prolonged obesity induces persistent changes in neural circuitry which helps maintain this “set point”, these include hypothalamic nuclei/pathways [9] as well as cognitive neurocircuits that regulate behavioural inhibition [10] and PFC function [11]. After weight loss caused by dieting, the brain attempts to return the body to the obese weight, resulting in heightened neural signals to stimulate food intake and decrease energy expenditure [8]. Considering that the phenomenon of weight loss-resistant obesity is driven by enduring structural changes within neural circuits regulating feeding behaviour and energy homeostasis, a potential therapeutic strategy to facilitate weight loss is to promote structural plasticity within the brain. Recent studies have demonstrated that even a single administration of psychedelic compounds, such as psilocybin, promotes neural plasticity in mice caused by a rapid and persistent growth of dendritic spines, which can facilitate the remodelling of neural circuits [12–14]. Psilocybin is metabolised to the active compound psilocin, which binds to an array of receptors within the central nervous system [15]. Psilocin has particularly high affinity for serotonin (5-HT) receptors, especially the 5-HT2AR subtype; binding to which is necessary for eliciting its psychoactive/hallucinatory effects [15]. Recent studies have also demonstrated that the promotion of structural plasticity of many psychedelics is mediated via an intracellular signalling pathway involving brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin receptor kinase B [TrkB; 13, 16]. In rodents, both anti-depressant [17–19] and anti-anxiolytic [20, 21] effects of psychedelics, even from a single administration, have been observed independently of 5-HT2AR activation; emphasising the importance of other modes of synaptic plasticity to drive beneficial changes. Obesity shares several common neural circuits and underlying mechanisms with substance abuse and addiction disorders [8, 22]. This manifestation of obesity, driven predominantly by excessive food intake and cravings for palatable food despite the adverse health outcomes, can be likened to the drug seeking observed in substance use disorders. Similarly, the regain of weight and return to the obese “set point” following dieting attempts may be comparable to a relapse of substance use after periods of abstinence. There have been numerous clinical trials conducted using varying psychedelic compounds for substance use disorders, with initial trials demonstrating psilocybin may be effective particularly for alcohol and tobacco use disorders [for review see 23]. In rodents, a non-hallucinogenic psychedelic analogue was able to reduce both alcohol- and heroin-seeking behaviour and intake [20], suggesting psychedelic-promoted neural plasticity may influence addiction-related circuits. Given the cross-over between addiction and obesity, it is plausible psychedelic compounds could inhibit the desire for palatable food (e.g., high-fat diet (HFD)), or food in general, in the same way they inhibit the seeking of drugs or alcohol. Psychedelics have been shown to promote neural plasticity by binding with high affinity to TrkB receptors [16]. Psychedelics act as potent allosteric modulators of TrkB to enhance BDNF signalling, indicating that only active synapses are strengthened, and the exacerbated neural remodelling is largely dependent on external input [16]. TrkB receptors are expressed in nuclei within the hypothalamus that play a critical role in regulating feeding behaviour and appetite such as the dorsomedial hypothalamus (DMH) and the paraventricular nucleus of the hypothalamus (PVN). The deletion of DMHTrkB neurons promotes hyperphagia and obesity in mice [24], and the activation of DMHTrkB or PVNTrkB neurons suppresses appetite and feeding [24–26]. DMHTrkB neurons are also activated in response to feeding or fasting [24], highlighting their role in the regulation of energy expenditure, and plausibly providing the external input to promote psychedelic-induced neural plasticity via enhanced BDNF signalling. Further investigation into the potential therapeutic benefits that psychedelic compounds such as psilocybin have for obesity is warranted [27]. In a recent study, no significant impact of psilocybin was observed on feeding and body weight parameters in diet-induced obese (DIO) mice switched onto low-fat chow, to mimic the effects of dieting in humans [28]. However, the diet intervention period in this study only lasted for 6 days, before the mice were re-fed HFD [28]. This period of time may be too short to capture the peak of synaptic spine density and structural remodelling that occurs approximately 7 days post-administration [12]. Therefore, the aim of the present study was to assess the longer-term influence of a single dose of psilocybin (1 mg/kg) on body weight, food intake and energy expenditure in DIO mice switched onto a low-fat chow. Materials and methods Animals Wild type male C57BL/6 J mice were obtained from the Monash Animal Research Platform (MARP; Clayton, VIC, Australia). Mice were 7 weeks of age when diet interventions began. Sawdust and tissue paper nesting material were provided throughout. All mice were housed under a 12:12 light cycle (lights off at 1900h). Rodent food (high-fat diet (HFD) or Chow – see details below) and water were available ad libitum. All experimentation was performed in accordance with the Prevention of Cruelty to Animals Act (2004), under the guidelines of the National Health and Medical Research Council Code of Practice for the Care and Use of Animals for Experimental Purposes in Australia (2013) and approved by the Monash Animal Research Platform Ethics Committee (ERM Project ID: 31107 and 37101). All efforts were made to minimise any animal suffering. Further animal details can be found in the Supplementary Materials and Methods. Pharmacological compounds Psilocybin (USONA Institute Investigational Drug Supply Program; Lot# AMS0167) was dissolved in saline (Baxter Healthcare Pty Ltd, NSW, Australia) and administered at a dose of 1 mg/kg. Dose selection was based on previous literature using psilocybin in mice [12, 17, 18]. All mice received a sham injection of 0.9% saline the day prior to receiving either 1 mg/kg psilocybin (PSI) or saline (SAL). All compounds were administered during the inactive phase typically between 1100-1300 h. All compounds were administered intraperitoneally using a 29 G needle in a volume of 5 mL/kg. Diets To promote diet-induced obesity (DIO), mice were fed a high-fat diet (HFD; SF04-001, Specialty Feeds, Glen Forest, WA, Australia) containing 43% digestible energy from lipids and 21% digestible energy from protein. An Irradiated Rat and Mouse Diet (Chow; SF00-100, Specialty Feeds, Glen Forest, WA, Australia) containing 11% digestible energy from lipids and 23% digestible energy from protein was used as a low-fat diet to promote weight loss. Supplementary Table 1 shows the high-level macronutrient contents of each diet. Detailed specifications for each diet can be found on the Specialty Feeds website: HFD; Chow. Experimental study design Male C57BL/6 J mice were randomly assigned to one of four groups: HFD-SAL; HFD-PSI; Chow-SAL or Chow-PSI. The experimental timeline is presented in Fig. 1. Briefly, 7-week-old mice were given access to HFD for 16-20 weeks to promote DIO (Supplementary Fig. 1, 2A) and remained group-housed. Body weights and food intake (per cage) were measured weekly during this period. One month prior to the psilocybin injection (designated day 0) all mice were single housed. For the next 24 days, body weights and food intake were measured three times per week as the mice acclimatised to single housing. A subset of mice (n = 32) were transferred to PhenoMaster indirect calorimetry / metabolic cages (PhenoMaster, TSE Systems, Germany) for the last 10 days of the 24-day single housing acclimatisation period, in preparation for indirect calorimetry recordings (see below). From day -8 onwards, body weight and food intake were measured daily. On day -1, all mice received a sham injection of saline. On day 0, all mice received an injection of either 1 mg/kg psilocybin (PSI) or 0.9% saline (SAL). On day 2, mice were either switched onto a Chow diet or remained on HFD. Mice were maintained on their respective diets for 28 days, after which all mice were humanely euthanised and tissue samples collected. Mice entered the protocol in staggered cohorts of up to 16 mice at a time, with treatments pseudo-randomly allocated within each cohort. The experimenter was blinded to treatment (PSI vs SAL) but not diet (HFD vs Chow) due to the distinct visual differences between diets.Fig. 1Experimental timeline.Male C57BL/6 J mice were fed a high-fat diet (HFD) over 16-20 weeks to promote diet-induced obesity (DIO) and were then single housed. 18 days prior to treatment administration (denoted day 0), DIO mice were acclimatised to TSE PhenoMaster metabolic cages/system over 15 days. A 24 h Baseline PhenoMaster recording was performed, and mice were then given an intraperitoneal (I.P) sham injection of 0.9% saline on day -1. On day 0, mice were administered either 1 mg/kg psilocybin (PSI) or saline (SAL). A 24 h Post-injection PhenoMaster recording was performed, and then half of the mice had their diet switched to a low-fat Chow, whilst the other half were maintained on HFD. Mice were maintained on their respective diets for 28 days and body weight and food intake were measured daily. 24 h PhenoMaster recordings were subsequently performed once per week throughout the diet intervention period. On day 30, mice were culled and tissue samples were collected. Experimental timeline. Male C57BL/6 J mice were fed a high-fat diet (HFD) over 16-20 weeks to promote diet-induced obesity (DIO) and were then single housed. 18 days prior to treatment administration (denoted day 0), DIO mice were acclimatised to TSE PhenoMaster metabolic cages/system over 15 days. A 24 h Baseline PhenoMaster recording was performed, and mice were then given an intraperitoneal (I.P) sham injection of 0.9% saline on day -1. On day 0, mice were administered either 1 mg/kg psilocybin (PSI) or saline (SAL). A 24 h Post-injection PhenoMaster recording was performed, and then half of the mice had their diet switched to a low-fat Chow, whilst the other half were maintained on HFD. Mice were maintained on their respective diets for 28 days and body weight and food intake were measured daily. 24 h PhenoMaster recordings were subsequently performed once per week throughout the diet intervention period. On day 30, mice were culled and tissue samples were collected. Indirect calorimetry (TSE PhenoMaster) To assess energy expenditure and substrate utilisation, mice underwent indirect calorimetry recordings using a PhenoMaster System (TSE Systems, Germany). Mice were habituated to indirect calorimetry / metabolic cages for 10 days from day -18 to -9. Mice were placed inside the PhenoMaster System from day -8 to -5 to acclimatise to the chamber environment. 24 h baseline recording data was collected between day -4 and -2 and 24 h post-injection recording data was collected between day 1 and 2. Mice were maintained on HFD or were switched from HFD to Chow on day 2 and thereafter 24 h recording data was collected once per week for the next 4 weeks. Body weight and food intake were manually measured once per day during indirect calorimetry assessments. Oxygen consumption, carbon dioxide expiration and respiratory exchange ratio (RER) were automatically collected every 36 min. All recordings were performed at 23°C and 50% humidity. The sample flow rate was 0.25 L/min. Immunohistochemistry (IHC) Immunostaining was performed on sections containing the medial prefrontal cortex (mPFC), dorsomedial hypothalamus (DMH) and paraventricular nucleus of the hypothalamus (PVN) using antibodies against PSD-95 (1:1000, catalogue number: MA1-046; ThermoFisher Scientific, Scoresby, VIC, Australia) and synapsin-1 (1:1000, catalogue number: #5297, Cell Signaling Technology, Danvers, MA, USA). Image processing and analysis was performed using Fiji/Image J [29] and CellProfiler™ [30] software. Detailed information regarding IHC procedures, including brain tissue collection/preparation, cryosectioning, immunostaining and imaging and analysis can be found in the Supplementary Materials and Methods. Data and statistical analysis Statistical analyses were performed using GraphPad Prism (version 10.2.2 for Windows) or R (version 4.1.3)/RStudio (version 2022.02.1 Build 461). For all analyses, P < 0.05 was considered statistically significant. Detailed data and statistical analyses can be found in the Supplementary Materials and Methods. Tabular summaries of statistical model analyses outputs and post hoc comparisons are presented in Supplementary Tables 2-15. Results Psilocybin exacerbates diet-induced weight loss in DIO mice To investigate the influence of psilocybin on body weight homeostasis, we injected DIO mice with 1 mg/kg psilocybin (or 0.9% saline) and then switched their food to a low-fat Chow or maintained them on HFD for a period of 28 days. Studies in group-housed mice demonstrated greater weight loss in Chow-PSI mice compared with Chow-SAL mice, which only became apparent approximately two weeks into the diet intervention (Supplementary Fig. 2D; Supplementary Table 2, 3). Psilocybin had no effect on body weight in DIO mice maintained on HFD and they continued to gain weight at the same trajectory as saline treated mice (Supplementary Fig. 2D, E). Additional cohorts of mice were single housed to investigate feeding behaviour and energy expenditure in greater detail. In the overall dataset, exacerbated diet-induced weight loss was observed in Chow-PSI mice compared with Chow-SAL mice (Fig. 2A; Supplementary Table 4, 5).Fig. 2Psilocybin increases susceptibility to diet-induced weight loss.A Daily body weight change (percentage from baseline) throughout the intervention period. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Chow-SAL, by multiple linear regression with Tukey’s multiple comparisons test. B Body weight change (percentage from baseline) at the conclusion of the intervention period. Black horizontal line at -13% denotes the threshold for weight loss resistant or weight loss susceptible mice. # denotes main effect of diet, ###P < 0.001 vs. HFD, by two-way ANOVA. Data are mean ± SEM. n = 19-28 per group. C Body weight change (percentage from baseline) at the conclusion of the intervention period in resistant and susceptible Chow fed mice. ***P < 0.001, by Student’s t-test. Data are mean ± SEM. Resistant: n = 30; Susceptible: n = 23. D Proportion of saline or psilocybin treated mice becoming resistant or susceptible to diet-induced weight loss. *P < 0.05, by Fisher’s exact test. E, F Individual traces of daily body weight change (percentage from baseline) throughout the intervention period for Chow-SAL mice (E) and Chow-PSI mice (F). Black horizontal line at -13% denotes the threshold for weight loss resistant or weight loss susceptible mice. SAL: n = 25; PSI: n = 28. G Proportion of weight loss resistant or weight loss susceptible mice treated with either saline or psilocybin. *P < 0.05, by Fisher’s exact test. Psilocybin increases susceptibility to diet-induced weight loss. A Daily body weight change (percentage from baseline) throughout the intervention period. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Chow-SAL, by multiple linear regression with Tukey’s multiple comparisons test. B Body weight change (percentage from baseline) at the conclusion of the intervention period. Black horizontal line at -13% denotes the threshold for weight loss resistant or weight loss susceptible mice. # denotes main effect of diet, ###P < 0.001 vs. HFD, by two-way ANOVA. Data are mean ± SEM. n = 19-28 per group. C Body weight change (percentage from baseline) at the conclusion of the intervention period in resistant and susceptible Chow fed mice. ***P < 0.001, by Student’s t-test. Data are mean ± SEM. Resistant: n = 30; Susceptible: n = 23. D Proportion of saline or psilocybin treated mice becoming resistant or susceptible to diet-induced weight loss. *P < 0.05, by Fisher’s exact test. E, F Individual traces of daily body weight change (percentage from baseline) throughout the intervention period for Chow-SAL mice (E) and Chow-PSI mice (F). Black horizontal line at -13% denotes the threshold for weight loss resistant or weight loss susceptible mice. SAL: n = 25; PSI: n = 28. G Proportion of weight loss resistant or weight loss susceptible mice treated with either saline or psilocybin. *P < 0.05, by Fisher’s exact test. Psilocybin increases susceptibility to diet-induced weight loss There was reasonable variability in the diet-induced weight loss response of DIO mice. Percentage weight loss at the conclusion of the 28-day diet intervention ranged from 1.77 to 24.79%. Based on the average weight loss of Chow-fed mice, DIO mice were categorised as either being resistant ( <13% weight loss) or susceptible ( >13% weight loss) to diet-induced weight loss (Fig. 2B). The average weight loss of resistant and susceptible mice was 8.20 and 18.16%, respectively (p < 0.0001; Fig. 2C). Psilocybin treatment significantly increased the probability of mice being susceptible to diet-induced weight loss (p = 0.012; Fig. 2D). Overall, 17 of 28 (60.71%) Chow-PSI mice were susceptible to diet-induced weight loss, compared with only 6 of 25 (24.00%) Chow-SAL mice (Fig. 2D), hence psilocybin treated mice were ~2.5 times more likely to be susceptible to profound diet-induced weight loss, compared with saline. Individual body weight change traces indicated most Chow-SAL mice were clustered either at or above the 13% threshold, with the exception of 3 mice which lost a considerable amount of weight (all >22%), although were not statistical outliers (Fig. 2E). In Chow-PSI mice, the distribution was shifted towards greater weight loss, with more than half of the mice in the susceptible range (Fig. 2F). Of the 30 mice deemed weight loss resistant, only 11 (36.67%) were treated with psilocybin. Conversely, 17 of the 23 (73.91%) susceptible mice were treated with psilocybin (Fig. 2G). Certain cohorts of mice were all single housed during diet interventions to obtain accurate food intake measurements and assess energy expenditure in TSE PhenoMaster indirect calorimetry / metabolic cages. Data from this set of mice only is shown in Figs. 3 and 4. The weight trajectories for single-housed Chow and HFD fed mice (Fig. 3A-F) were comparable to those observed in group-housed mice (Supplementary Fig. 2B-E). In this subset of mice, when assessing percentage body weight change, there was a main effect of diet but no significant difference between Chow-PSI and Chow-SAL mice (Fig. 3D; Supplementary Table 6, 7). This data subset, however, appears to be heavily influenced by a single mouse in the saline group which exhibited prominent weight loss (-23.63%), which skews the data towards non-significance (Fig. 3B, E). Despite being >2 standard deviations (SD = 5.25%) below the group mean (-9.09%), this mouse was not a statistical outlier, and we have no other justification to exclude it. Within this subset, the average weight loss of resistant and susceptible mice was 7.88% and 16.64%, respectively (p < 0.0001; Fig. 3F). Furthermore, 7 of the 8 (87.50%) weight loss susceptible mice were treated with psilocybin, compared to only 9 of 23 (39.13%) weight loss resistant mice, emphasising that psilocybin increases the proportion of mice susceptible to diet-induced weight loss.Fig. 3Psilocybin increases susceptibility to reduce food intake when undergoing diet interventions.A Daily body weight throughout the intervention period. Inset graph shows body weight at the conclusion of the diet-induced obesity (DIO) phase. B, C Body weight change from baseline (day 0) at the conclusion of the intervention period in all treatment groups (B) and resistant and susceptible Chow fed mice (C). D Daily body weight change (percentage from baseline) throughout the intervention period. E Body weight change (percentage from baseline) at the conclusion of the intervention period. Black horizontal line at -13% denotes the threshold for weight loss resistant or weight loss susceptible mice. F Body weight change (percentage from baseline) at the conclusion of the intervention period in resistant and susceptible Chow fed mice. G Cumulative food intake throughout the diet intervention period. H, I Total food intake during the diet intervention period in all treatment groups (H) and in resistant and susceptible Chow fed mice (I). J Cumulative energy intake throughout the diet intervention period. K, L Total energy intake during the diet intervention period in all treatment groups (K) and in resistant and susceptible Chow fed mice (L). M, N Feeding efficiency (percentage body weight change per kJ consumed) at the conclusion of the intervention period in all treatment groups (M) and in resistant and susceptible Chow fed mice (N). A, D, G, J: † denotes overall main effect of diet, # denotes main effect of diet at individual day. †††P < 0.001 vs. HFD, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. HFD, by multiple linear regression with Tukey’s multiple comparisons test. B, E, H, K, M: # denotes main effect of diet. ###P < 0.001 vs. HFD, by two-way ANOVA. C, F, I, L, N: **P < 0.01, ***P < 0.001, by Student’s t-test. All data are mean ± SEM. HFD-SAL n = 14; HFD-PSI: n = 15; Chow-SAL: n = 15; Chow-PSI: n = 16; Resistant: n = 23; Susceptible: n = 8.Fig. 4Psilocybin increases susceptibility to reduce energy intake when undergoing diet interventions.A Daily energy intake pre- and post-injection of PSI or SAL. B, C Comparisons of average pre- and post-injection energy intake for all treatment groups (B) and in resistant and susceptible Chow fed mice (C). D, E Post-injection energy intake (expressed as a percentage of pre-injection energy intake) for all treatment groups (D) and in resistant and susceptible Chow fed mice (E). Graphs F-J show corresponding data to graphs A-E, except that energy intake has been normalised to daily body weight. A, F: # denotes main effect of diet at individual day. ##P < 0.01, ###P < 0.001 vs. HFD, by multiple linear regression with Tukey’s multiple comparisons test. D, I: # denotes main effect of diet. ###P < 0.001 vs. HFD, by two-way ANOVA. C, E, H, J: **P < 0.01, ***P < 0.001, by Student’s t-test. B, G: ***P < 0.001, by Student’s paired t-test. All data are mean ± SEM except in B, C, G and H, which show mean only. HFD-SAL n = 14; HFD-PSI: n = 15; Chow-SAL: n = 15; Chow-PSI: n = 16; Resistant: n = 23; Susceptible: n = 8. Psilocybin increases susceptibility to reduce food intake when undergoing diet interventions. A Daily body weight throughout the intervention period. Inset graph shows body weight at the conclusion of the diet-induced obesity (DIO) phase. B, C Body weight change from baseline (day 0) at the conclusion of the intervention period in all treatment groups (B) and resistant and susceptible Chow fed mice (C). D Daily body weight change (percentage from baseline) throughout the intervention period. E Body weight change (percentage from baseline) at the conclusion of the intervention period. Black horizontal line at -13% denotes the threshold for weight loss resistant or weight loss susceptible mice. F Body weight change (percentage from baseline) at the conclusion of the intervention period in resistant and susceptible Chow fed mice. G Cumulative food intake throughout the diet intervention period. H, I Total food intake during the diet intervention period in all treatment groups (H) and in resistant and susceptible Chow fed mice (I). J Cumulative energy intake throughout the diet intervention period. K, L Total energy intake during the diet intervention period in all treatment groups (K) and in resistant and susceptible Chow fed mice (L). M, N Feeding efficiency (percentage body weight change per kJ consumed) at the conclusion of the intervention period in all treatment groups (M) and in resistant and susceptible Chow fed mice (N). A, D, G, J: † denotes overall main effect of diet, # denotes main effect of diet at individual day. †††P < 0.001 vs. HFD, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. HFD, by multiple linear regression with Tukey’s multiple comparisons test. B, E, H, K, M: # denotes main effect of diet. ###P < 0.001 vs. HFD, by two-way ANOVA. C, F, I, L, N: **P < 0.01, ***P < 0.001, by Student’s t-test. All data are mean ± SEM. HFD-SAL n = 14; HFD-PSI: n = 15; Chow-SAL: n = 15; Chow-PSI: n = 16; Resistant: n = 23; Susceptible: n = 8. Psilocybin increases susceptibility to reduce energy intake when undergoing diet interventions. A Daily energy intake pre- and post-injection of PSI or SAL. B, C Comparisons of average pre- and post-injection energy intake for all treatment groups (B) and in resistant and susceptible Chow fed mice (C). D, E Post-injection energy intake (expressed as a percentage of pre-injection energy intake) for all treatment groups (D) and in resistant and susceptible Chow fed mice (E). Graphs F-J show corresponding data to graphs A-E, except that energy intake has been normalised to daily body weight. A, F: # denotes main effect of diet at individual day. ##P < 0.01, ###P < 0.001 vs. HFD, by multiple linear regression with Tukey’s multiple comparisons test. D, I: # denotes main effect of diet. ###P < 0.001 vs. HFD, by two-way ANOVA. C, E, H, J: **P < 0.01, ***P < 0.001, by Student’s t-test. B, G: ***P < 0.001, by Student’s paired t-test. All data are mean ± SEM except in B, C, G and H, which show mean only. HFD-SAL n = 14; HFD-PSI: n = 15; Chow-SAL: n = 15; Chow-PSI: n = 16; Resistant: n = 23; Susceptible: n = 8. Psilocybin does not influence food intake in DIO mice maintained on HFD Food intake was measured daily prior to and beyond the drug and diet interventions (see Fig. 1). Psilocybin had no influence on HFD food (and energy) intake in DIO mice (Fig. 3G, H, K, L). Average energy intake was not different pre- and post-psilocybin injection (Fig. 4A, B, D, F, G, I). Psilocybin also had no influence on HFD food intake in DIO mice that underwent Chow diet interventions and were later re-introduced to HFD (Supplementary Fig. 3). These data indicate psilocybin does not decrease the desire for palatable food, at least when that food source is freely available. Psilocybin increases susceptibility to reduce food intake when undergoing diet interventions DIO mice reduced food intake for several days after the diet intervention period began as they adjusted to the less palatable Chow diet. Thereafter, daily HFD and Chow food intake was generally equivalent, and overall food intake for the 28-day intervention period was not different between any of the groups (Fig. 3H). Given the difference in caloric density between the two diets, overall energy intake was significantly reduced in Chow mice compared with HFD mice (Fig. 3J, K). Psilocybin had no overall effect on food and energy intake for Chow mice throughout the diet intervention period (Fig. 3G, H, J, K; Supplementary Table 8, 9). Despite no overall impact on food intake, weight loss susceptible mice (7 of 8 treated with psilocybin) had significantly reduced food and energy intake (p = 0.0025; Fig. 3I, L), and a reduced feeding efficiency (p < 0.0001; Fig. 3N), suggesting weight loss relative to food intake was exacerbated compared with weight loss resistant mice. Daily energy intake was significantly reduced post-injection compared to pre-injection for Chow mice (Fig. 4A, B, D; Supplementary Table 10, 11), an effect that was also present when daily energy intake was normalised to body weight (Fig. 4F, G, I; Supplementary Table 10, 11). Psilocybin did not have an overall effect on these parameters in Chow mice (Fig. 4D, I), however, weight loss susceptible mice significantly reduced post-injection energy intake as a percentage of pre-injection (or baseline) energy intake, compared with weight loss resistant mice (Fig. 4E, J). Psilocybin does not affect metabolism or energy expenditure To assess the effects of psilocybin on whole body metabolism and energy expenditure, we performed 24 h indirect calorimetry measurements once per week over the course of the 28-day diet intervention period. Oxygen consumption (VO2) was not different at baseline or post-injection but was decreased in Chow mice compared to HFD mice from Week 1 to 4 (Supplementary Fig. 4A-D). Carbon dioxide expiration was not different between any of the groups at any timepoint measured throughout the experiment (Supplementary Fig. 4F-I). Respiratory exchange ratio (RER) was not different at baseline or post-injection but was increased in Chow mice compared with HFD mice from Week 1 to Week 4 (Fig. 5A-D; Supplementary Table 12), as Chow mice began to utilise carbohydrates rather than fat as a fuel source. Psilocybin did not have an impact on any of these parameters in HFD or Chow fed mice.Fig. 5Psilocybin does not influence respiratory gas exchange.A-D Respiratory exchange ratio (RER) over a 24 h recording. E Mean RER plotted across each recording timepoint. Dark shade represents the active phase. A-D: # denotes main effect of diet at individual time. #P < 0.05, ##P < 0.01, ###P < 0.001 vs. HFD, by multiple linear regression with Tukey’s multiple comparisons test. E: ***P < 0.001 vs. HFD-SAL and HFD-PSI, by repeated measures two-way ANOVA with Tukey’s multiple comparisons test. Data are mean ± SEM. n = 6-8 per group, per recording timepoint. Psilocybin does not influence respiratory gas exchange. A-D Respiratory exchange ratio (RER) over a 24 h recording. E Mean RER plotted across each recording timepoint. Dark shade represents the active phase. A-D: # denotes main effect of diet at individual time. #P < 0.05, ##P < 0.01, ###P < 0.001 vs. HFD, by multiple linear regression with Tukey’s multiple comparisons test. E: ***P < 0.001 vs. HFD-SAL and HFD-PSI, by repeated measures two-way ANOVA with Tukey’s multiple comparisons test. Data are mean ± SEM. n = 6-8 per group, per recording timepoint. Energy expenditure (kcal/h) was not different at baseline or post-injection but was decreased in Chow mice compared to HFD mice from Week 1 to 4 (Supplementary Fig. 5A-D). Energy expenditure per body weight (kcal/h/kg) was not different at baseline or post-injection but was decreased in Chow mice compared with HFD mice at Week 1 (Fig. 6A), Week 3 (Fig. 6C) and Week 4 (Fig. 6D) timepoints (Supplementary Table 13). Psilocybin did not have an impact on any of these parameters in HFD or Chow fed mice. Together, these data suggest psilocybin increases susceptibility to diet-induced weight loss predominantly through reduced food intake, as opposed to enhanced energy expenditure or altered substrate utilisation.Fig. 6Psilocybin does not influence energy expenditure.A-D Energy expenditure per body weight (kcal/h/kg) over a 24 h recording. E Mean energy expenditure per body weight plotted across each recording timepoint. A-D: † denotes overall main effect of diet. ††P < 0.01 vs. HFD, by multiple linear regression with Tukey’s multiple comparisons test. E: † denotes overall main effect of diet. †††P < 0.001 vs. HFD, by repeated measures two-way ANOVA with Tukey’s multiple comparisons test. Data are mean ± SEM. n = 6-8 per group, per recording timepoint. Psilocybin does not influence energy expenditure. A-D Energy expenditure per body weight (kcal/h/kg) over a 24 h recording. E Mean energy expenditure per body weight plotted across each recording timepoint. A-D: † denotes overall main effect of diet. ††P < 0.01 vs. HFD, by multiple linear regression with Tukey’s multiple comparisons test. E: † denotes overall main effect of diet. †††P < 0.001 vs. HFD, by repeated measures two-way ANOVA with Tukey’s multiple comparisons test. Data are mean ± SEM. n = 6-8 per group, per recording timepoint. Psilocybin did not change levels of synaptic proteins in the prefrontal cortex or hypothalamus To investigate any potential changes in psilocybin-induced synaptic plasticity in the brain, immunostaining was performed for the pre-synaptic protein synapsin-1 and post-synaptic protein PSD-95. Psilocybin had no influence on positive puncta of synapsin-1, PSD-95 or co-localisation of both proteins (i.e., synapses) in the mPFC (Fig. 7C-E), PVN (Fig. 8C-E) or DMH (Fig. 9C-E). We did observe a main effect of diet, whereby Chow decreased the positive puncta of PSD-95 (and subsequently also synapses) in the mPFC (Fig. 7C, E) and DMH (Fig. 9C, E).Fig. 7Levels of PSD-95 and synapsin-1 in the mPFC following psilocybin treatment.A Representative images of immunostaining in the medial prefrontal cortex (mPFC) in mouse brains 30 days post-psilocybin injection (DAPI: cyan; PSD-95: yellow; synapsin-1: magenta). Scale bar: 20 µm. B The diagram shows the relevant section from the mouse brain atlas. Imaging was performed in the PrL and IL regions of the mPFC which are highlighted in green. C-E Number of positive puncta for PSD-95 (C) synapsin-1 (D) and total synapses (co-localisation of both markers; E in the mPFC. # denotes main effect of diet, ##P < 0.01 vs. HFD, by two-way ANOVA. Data are mean ± SEM. n = 5-6 per group.Fig. 8Levels of PSD-95 and synapsin-1 in the PVN following psilocybin treatment.A Representative images of immunostaining in the paraventricular nucleus of the hypothalamus (PVN) in mouse brains 30 days post-psilocybin injection (DAPI: cyan; PSD-95: yellow; synapsin-1: magenta). Scale bar: 20 µm. B The diagram shows the relevant section from the mouse brain atlas. Imaging was performed in the PaLM and PaMM regions of the PVN which are highlighted in green. C-E Number of positive puncta for PSD-95 (C), synapsin-1 (D) and total synapses (co-localisation of both markers; E in the PVN. Data are mean ± SEM. n = 5-6 per group.Fig. 9Levels of PSD-95 and synapsin-1 in the DMH following psilocybin treatment.A Representative images of immunostaining in the dorsomedial nucleus of the hypothalamus (DMH) in mouse brains 30 days post-psilocybin injection (DAPI: cyan; PSD-95: yellow; synapsin-1: magenta). Scale bar: 20 µm. B The diagram shows the relevant section from the mouse brain atlas. Imaging was performed in the DM region of the DMH which is highlighted in green. C-E Number of positive puncta for PSD-95 (C), synapsin-1 (D) and total synapses (co-localisation of both markers; E in the DMH. # denotes main effect of diet, ##P < 0.01 vs. HFD, by two-way ANOVA. Data are mean ± SEM. n = 5-6 per group. Levels of PSD-95 and synapsin-1 in the mPFC following psilocybin treatment. A Representative images of immunostaining in the medial prefrontal cortex (mPFC) in mouse brains 30 days post-psilocybin injection (DAPI: cyan; PSD-95: yellow; synapsin-1: magenta). Scale bar: 20 µm. B The diagram shows the relevant section from the mouse brain atlas. Imaging was performed in the PrL and IL regions of the mPFC which are highlighted in green. C-E Number of positive puncta for PSD-95 (C) synapsin-1 (D) and total synapses (co-localisation of both markers; E in the mPFC. # denotes main effect of diet, ##P < 0.01 vs. HFD, by two-way ANOVA. Data are mean ± SEM. n = 5-6 per group. Levels of PSD-95 and synapsin-1 in the PVN following psilocybin treatment. A Representative images of immunostaining in the paraventricular nucleus of the hypothalamus (PVN) in mouse brains 30 days post-psilocybin injection (DAPI: cyan; PSD-95: yellow; synapsin-1: magenta). Scale bar: 20 µm. B The diagram shows the relevant section from the mouse brain atlas. Imaging was performed in the PaLM and PaMM regions of the PVN which are highlighted in green. C-E Number of positive puncta for PSD-95 (C), synapsin-1 (D) and total synapses (co-localisation of both markers; E in the PVN. Data are mean ± SEM. n = 5-6 per group. Levels of PSD-95 and synapsin-1 in the DMH following psilocybin treatment. A Representative images of immunostaining in the dorsomedial nucleus of the hypothalamus (DMH) in mouse brains 30 days post-psilocybin injection (DAPI: cyan; PSD-95: yellow; synapsin-1: magenta). Scale bar: 20 µm. B The diagram shows the relevant section from the mouse brain atlas. Imaging was performed in the DM region of the DMH which is highlighted in green. C-E Number of positive puncta for PSD-95 (C), synapsin-1 (D) and total synapses (co-localisation of both markers; E in the DMH. # denotes main effect of diet, ##P < 0.01 vs. HFD, by two-way ANOVA. Data are mean ± SEM. n = 5-6 per group. Discussion Recently, there has been considerable interest in the therapeutic potential of psychedelic compounds for the treatment of depression and/or anxiety- and addiction-like disorders [31, 32], due at least in part, to the ability of these compounds to promote rapid and persistent dendritic growth [12, 13]. These neuropsychiatric disorders are commonly characterised by cognitive inflexibility and permanent synaptic and structural changes, which often make them highly resistant to standard treatment modalities or interventions [33, 34]. Neuropsychiatric disorders, such as depression, share several underlying mechanisms and neural circuits with obesity, and depression and obesity are commonly comorbid conditions [35]. Weight loss-resistant obesity is indeed driven by enduring structural changes within neural circuits regulating feeding behaviour and energy homeostasis [8]. Therefore, psychedelic-induced enhanced structural plasticity has been proposed as a novel therapeutic strategy for the treatment of obesity. In this study, we demonstrate that a single dose of the psychedelic compound psilocybin exacerbated and increased susceptibility to profound weight loss following prolonged ( > 14 days) diet interventions in obese mice. Intensive lifestyle, behavioural and diet interventions can be extremely effective for rapid and short-term weight loss, however, most individuals regain this weight. This phenomenon can be attributed to several mechanisms that promote and facilitate weight regain, in an attempt to return the body to a homeostatic obese “set point” [7]. These mechanisms include reduced lipolysis and increased triglyceride synthesis, altered hunger and satiety signalling, decreased energy expenditure, and modified reward signalling in response to food [7]. Importantly, many of these mechanisms are impacted by obesity-driven persistent structural changes within neural circuits regulating these processes [8]. In agreement with previous literature [28], we did not observe a difference in weight regain following psilocybin administration in dieted DIO mice that were then re-introduced to HFD (lean, HFD-naïve mice also gained weight at a comparable rate when introduced to HFD). These findings suggest that psilocybin does not appear to defend against weight regain, at least with these experimental paradigms used. Intriguingly, in the current study, psilocybin was able to exacerbate diet-induced weight loss in DIO mice and increased the susceptibility for mice to exhibit more profound weight loss in response to dieting. This result is in contradiction to previously published findings that showed no difference between saline and psilocybin in the weight loss trajectory of DIO mice fed a low-fat chow [28]. In that study, the diet intervention period lasted for 6 days, before the mice were re-fed HFD. After 6 days of diet intervention, we similarly observed no difference between saline and psilocybin treated mice, however, after >14 days of the intervention the percentage weight loss curves of the two groups began to diverge significantly. These findings may be attributable to the fact that for psilocybin the peak synaptic spine density and structural remodelling occurs approximately 7 days post-administration [12]. If promoting increased synaptic density and plasticity is indeed a mechanism by which psilocybin is exerting its effects on body weight, then 6 days of diet intervention may not be enough time for these effects to become apparent. It is plausible that if Fadahunsi et al. [28] had extended their diet intervention period, they may have observed similar results to those presented here. In the current study, we used a psilocybin dose of 1 mg/kg, which has been commonly reported in the literature [12, 17–19, 21, 36–38], compared with 3 mg/kg used by Fadahunsi et al. [28]. The contrasting results between the two studies suggests that the timing of interventions may be more important than the dosage, however, it is plausible that a higher dose may have exacerbated the effects observed in the present study. Based on the average weight loss of DIO-Chow mice, we categorised mice as either being resistant or susceptible to diet-induced weight loss. In conjunction with exacerbated weight loss, when switched to low-fat chow susceptible mice exhibited decreased food/energy intake, decreased feeding efficiency and decreased energy intake as a percentage of baseline DIO levels, compared with resistant mice. Of the susceptible mice in these cohorts, all but one of them received psilocybin, compared with ~40% receiving psilocybin in the resistant group. A reasonable proportion of mice therefore received psilocybin and did not show substantial decreases in body weight or food intake, however, of the mice that did show substantial changes, it was extremely likely that they received psilocybin. These data indicate that psilocybin does not necessarily promote extreme weight loss, but without psilocybin, it is very unlikely a mouse will be able to exhibit profound diet-induced weight loss. Furthermore, psilocybin did not promote any weight loss or reduce food intake in DIO mice maintained on HFD, in agreement with Fadahunsi et al. [28]. These findings highlight that psilocybin does not reduce the seeking or consumption of palatable food (at least when that food source is freely available), nor does it induce weight loss. Taken together with its impacts on dieted DIO mice, we hypothesise that psilocybin does not necessarily promote weight loss or reduce food intake per se, however, it can help facilitate or even exacerbate weight loss, provided it is administered in combination with other weight loss promoting interventions. Weight adjusted energy expenditure was not different between saline and psilocybin treated mice regardless of diet (HFD vs Chow), nor between resistant and susceptible mice, in alignment with psilocybin being reported to have no impact on indirect calorimetry measurements, even at a dose of 3 mg/kg [28]. These data indicate psilocybin exerts its effects predominantly through influencing feeding behaviour and food/energy intake rather than modulating energy expenditure. Recent studies have demonstrated that psychedelic compounds such as psilocybin can promote neural plasticity through a mechanism involving BDNF and its receptor TrkB [13, 16]. Importantly, psychedelics are not agonists for TrkB, but rather allosteric modulators of these receptors, indicating that only active synapses are strengthened, and any exacerbated neural remodelling is environmentally guided [16]. TrkB receptors are expressed in nuclei within the hypothalamus such as the PVN and DMH, which play a critical role in regulating and suppressing feeding behaviour [24–26]. Furthermore, a recent study showed enhanced c-fos expression in the PVN following psilocybin administration [21]. We hypothesised that the switch to low-fat chow and subsequent short-term changes in body weight and feeding behaviour would activate hypothalamic nuclei, allowing psilocybin to further potentiate any synaptic changes. This mechanism would indicate that psilocybin can likely not function independently to promote weight loss, rather it can only facilitate weight loss with interventions (i.e., dieting) that are already in place to alter adaptations within the hypothalamus (or perhaps other brain regions) that have developed as a result of obesity. This hypothesis aligns with the body weight and food intake data observed in the present study, whereby psilocybin was only able to facilitate weight loss in conjunction with a diet intervention but had no impact on DIO mice maintained on HFD. Future studies are required to conclusively prove if this mechanism is involved in the present findings. A recent study found that a single dose of psilocybin resulted in a subtle but significant increase in body weight, albeit with no effect on food or water intake, in male and female mice maintained on a standard chow diet [38]. Interestingly, this effect was still present when mice were pre-treated with the 5-HT2AR and 5-HT2CR antagonist ketanserin (2 mg/kg); suggesting the observed effects were driven by mechanisms independent of 5-HT2R activation [38]. Taken together, our data and published literature further support the concept that the influence of psilocybin on body weight, feeding behaviour and metabolism is likely context-dependent and reliant on external input/stimuli. In support of this is the recent finding that psilocybin restrains pathological weight loss in female rats undergoing the activity-based anorexia (ABA) paradigm, a model that pairs voluntary running wheel access with time-limited access to food [39]. This was correlated with enhanced cognitive flexibility in a reversal learning task and altered 5-HT transcriptional profiles in the mPFC, suggesting that the cognitive drivers of body weight maintenance in the ABA model were impacted, rather than the metabolic drivers. Owing to the increasing evidence that the PFC is a key site of psychedelic actions, perhaps the potential impact of psilocybin on obesity may be brought into sharper focus by examining the intersection between obesity and binge eating disorder [40], a condition that is typified by loss of control or emotional eating that is driven by deficits in impulse control [41] and PFC dysfunction [42]. Despite this hypothesis, we did not observe any changes in the synaptic proteins synapsin-1 or PSD-95 in the mPFC across any of the treatment groups, when the brains were collected 30 days post-injection. Although increased synaptic spine density was previously shown to persist for at least one month following a single administration of psilocybin, the peak density occurs at approximately day 7 [12] and hence by day 30 the differences may not have been substantial enough to be detected with the methods used here. Further experimentation using more advanced techniques (e.g., two-photon imaging to assess real-time changes in spine formation and density) is warranted to conclude whether psilocybin facilitates weight loss by modulating neural circuits and synaptic connections within prefrontal or hypothalamic nuclei in obese mice undergoing diet-induced weight loss. It is also possible that psilocybin’s facilitation of weight loss maintenance operates through mechanisms independent of sustained structural synaptic plasticity in these specific regions, or through plasticity in other brain regions not examined here. Future studies employing comprehensive circuit mapping and functional connectivity analyses will be necessary to fully elucidate the neural substrates mediating psilocybin’s effects on body weight regulation. In conclusion, we have demonstrated that a single dose of the psychedelic compound psilocybin exacerbated and increased susceptibility to profound weight loss following prolonged ( > 14 days) diet interventions in obese mice. Psilocybin had no influence on feeding behaviour or body weight in DIO mice maintained on HFD, indicating psilocybin does not directly promote weight loss or reduce food intake, but rather may help facilitate or exacerbate weight loss when administered in combination with other interventions, such as dieting. These findings suggest that psilocybin functions not as a conventional appetite suppressant, but as a catalyst for neuroadaptation during periods of behavioural change. The absence of effects in HFD-maintained mice, coupled with the significant potentiation of weight loss in mice undergoing dietary transition, indicates that psilocybin’s therapeutic potential for obesity may be maximized when administered in conjunction with lifestyle interventions. This aligns with the concept of ‘critical period’ reopening, wherein psychedelics temporarily enhance neural circuit malleability, allowing for more effective rewiring of maladaptive patterns when appropriate behavioural or environmental scaffolding is present [43, 44]. Future research should investigate optimal timing of psilocybin administration relative to dietary intervention. In agreement with current literature, psilocybin did not alter energy expenditure, suggesting it exerts its effects predominantly through influencing feeding behaviour and food intake. We hypothesised these effects could be mediated by psilocybin’s actions on TrkB receptors in hypothalamic nuclei such as the PVN and DMH, which play a key role in suppressing food intake. We were unable to provide any conclusive evidence to support such a hypothesis in the current study, although further experimentation is warranted to investigate this or other potential mechanisms. Nevertheless, we have provided functional evidence to support further investigation into the use of psychedelic compounds as an adjunct therapy for obesity. Supplementary information Supplementary Information Supplementary Information